Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, ElinzanetantBusiness Wire • 08/31/21
Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 DiabetesBusiness Wire • 08/28/21
Bayer Announces Filing of Petition to U.S. Supreme Court for Review of Hardeman DecisionBusiness Wire • 08/16/21
Berkeley Lights, Bayer Ink Discovery Pact For Next-Gen Traits In Agricultural Sector, Berkeley Q2 Earnings Miss EstimatesBenzinga • 08/11/21
Bayer's (BAYZF) CEO Werner Baumann on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion TherapeuticsBusiness Wire • 08/05/21
My Dividend Portfolio: July 2021 Update - 99 Holdings, 35 Buys, Dividend RecordSeeking Alpha • 08/05/21
Bayer Aktiengesellschaft (BAYRY) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 07/22/21
Bayer's Kerendia Scores Long-Awaited Kidney & Heart Disease Nod For Type 2 DiabetesBenzinga • 07/12/21